FXR shaped an immunosuppressive TME in NSCLC by inducing HVEM expression through transcriptional activation, intracellular Akt, Erk1/2 and STAT3 signaling pathways, and G1/S cycle progression. The gene discussed is MAPK3; the disease is non-small cell lung carcinoma.